Lipoarabinomannan

Uses

How it works

Benefits

Risks & contraindications

Where it comes from

Highlighted claims

• Lipoarabinomannan is a glycolipid component of the Mycobacterium tuberculosis cell wall. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya
• LAM has primarily been evaluated as a urine-based rapid diagnostic test, but its potential as a sputum-based treatment monitoring biomarker has emerged from recent research. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya
• Sputum LAM concentrations measured by ELISA correlated with bacterial load as determined by the MGIT culture system. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya
• LAM measurement requires sputum production, which may become difficult as patients improve clinically during treatment. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya
• Treatment-related LAM declines were particularly pronounced in patients with high baseline LAM levels. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya
• Sputum LAM declined in parallel with bacterial load during the first 14 days of treatment. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya